scholarly journals In VitroStudy of the Susceptibility of Clinical Isolates ofTrichomonas vaginalisto Metronidazole and Secnidazole

2018 ◽  
Vol 62 (4) ◽  
pp. e02329-17 ◽  
Author(s):  
Arindam P. Ghosh ◽  
Cheri Aycock ◽  
Jane R. Schwebke
Keyword(s):  
Disease Control ◽  
Standard Therapy ◽  
Trichomonas Vaginalis ◽  
Clinical Isolates ◽  
Emerg Infect ◽  
Content Type ◽  
Control And Prevention ◽  
Centers For Disease Control ◽  
Archived Specimens

ABSTRACTNitroimidazoles (metronidazole [MTZ] and tinidazole [TNZ]) are the only drugs recommended for treatment ofTrichomonas vaginalisinfections. MTZ resistance occurs in 4% to 10% of cases of vaginal trichomoniasis (R. D. Kirkcaldy et al., Emerg Infect Dis 18:939–943, 2012; J. R. Schwebke and F. J. Barrientes, Antimicrob Agents Chemother 50:4209–4210, 2006) and TNZ resistance in 1% of cases (J. R. Schwebke and F. J. Barrientes, Antimicrob Agents Chemother 50:4209–4210, 2006). Emerging nitroimidazole-resistant trichomoniasis is concerning, because few alternatives to standard therapy exist. We assessed the prevalence ofin vitroaerobic MTZ and secnidazole resistance amongT. vaginalisisolates collected in 2015 to 2016 from 100 women in Birmingham, Alabama, with positive cultures. Archived specimens were treated with secnidazole or MTZ (0.2 to 400 μg/ml) for 48 h, according to U.S. Centers for Disease Control and Prevention protocols. Ninety-six (96%) of the 100 clinicalTrichomonasisolates tested demonstrated lower minimum lethal concentrations for secnidazole than for MTZ, suggesting that secnidazole has betterin vitroactivity than MTZ.

scholarly journals CDC Warns of Increased Ivermectin Overdoses

2021 ◽  
Vol 23 (2) ◽  
pp. 62-63
Author(s):  
Richard Robbins ◽  
Keyword(s):  
Disease Control ◽  
River Blindness ◽  
The Us ◽  
Control And Prevention ◽  
Centers For Disease Control ◽  
In Cells

No abstract available. Article truncated after 150 words. The US Centers for Disease Control and Prevention (CDC) is warning of an increase in cases of ivermectin overdose due to people self-prescribing the drug in an effort to prevent or treat COVID-19 (1). Ivermectin is used to treat river blindness and intestinal roundworm infection in humans and to de-worm pets and livestock. A study published earlier this year showed that ivermectin killed SARS-CoV-2 in cells in vitro. The authors proposed that the medication be investigated as a cheap and easily available treatment for COVID-19. However, subsequent studies have failed to find any benefit in humans (3). In a new communication to its Health Alert Network, the CDC says cases of overdose and misuse are rising (1). More than 88,000 prescriptions were written for the drug ivermectin in the week ending August 13, an increase of 2400% over the weekly average prior to the COVID-19 pandemic (Figure 1). Unfortunately, the …

scholarly journals Mycobacterium tuberculosispncAPolymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT: TABLE 1

2015 ◽  
Vol 53 (11) ◽  
pp. 3633-3635 ◽  
Author(s):  
Michael G. Whitfield ◽  
Robin M. Warren ◽  
Elizabeth M. Streicher ◽  
Samantha L. Sampson ◽  
Frik A. Sirgel ◽  
...  
Keyword(s):  
South Africa ◽  
Mycobacterium Tuberculosis ◽  
Disease Control ◽  
Susceptibility Testing ◽  
Content Type ◽  
Control And Prevention ◽  
Centers For Disease Control ◽  
Susceptibility Breakpoint ◽  
The U.S

Sequencing of theMycobacterium tuberculosispncAgene allows for pyrazinamide susceptibility testing. We summarize data onpncApolymorphisms that do not confer resistance at a susceptibility breakpoint of 100 μg/ml pyrazinamide in MGIT within a cohort of isolates from South Africa and the U.S. Centers for Disease Control and Prevention.

The Speech-Language Pathologists' Role in Mild Traumatic Brain Injury for Middle and High School–Age Children: Viewpoints on Guidelines From the Centers for Disease Control and Prevention

2019 ◽  
Vol 28 (3) ◽  
pp. 1363-1370 ◽  
Author(s):  
Jessica Brown ◽  
Katy O'Brien ◽  
Kelly Knollman-Porter ◽  
Tracey Wallace
Keyword(s):  
High School ◽  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Disease Control ◽  
Mild Traumatic Brain Injury ◽  
School Age Children ◽  
School Age ◽  
Speech Language Pathologists ◽  
Control And Prevention ◽  
Centers For Disease Control

Purpose The Centers for Disease Control and Prevention (CDC) recently released guidelines for rehabilitation professionals regarding the care of children with mild traumatic brain injury (mTBI). Given that mTBI impacts millions of children each year and can be particularly detrimental to children in middle and high school age groups, access to universal recommendations for management of postinjury symptoms is ideal. Method This viewpoint article examines the CDC guidelines and applies these recommendations directly to speech-language pathology practices. In particular, education, assessment, treatment, team management, and ongoing monitoring are discussed. In addition, suggested timelines regarding implementation of services by speech-language pathologists (SLPs) are provided. Specific focus is placed on adolescents (i.e., middle and high school–age children). Results SLPs are critical members of the rehabilitation team working with children with mTBI and should be involved in education, symptom monitoring, and assessment early in the recovery process. SLPs can also provide unique insight into the cognitive and linguistic challenges of these students and can serve to bridge the gap among rehabilitation and school-based professionals, the adolescent with brain injury, and their parents. Conclusion The guidelines provided by the CDC, along with evidence from the field of speech pathology, can guide SLPs to advocate for involvement in the care of adolescents with mTBI. More research is needed to enhance the evidence base for direct assessment and treatment with this population; however, SLPs can use their extensive knowledge and experience working with individuals with traumatic brain injury as a starting point for post-mTBI care.

Sign in / Sign up

Export Citation Format

Share Document